Upcoming Events

Archive: September 2022

EHDN2022 Plenary Meeting

Topics presented during the EHDN2022 Plenary Meeting will contain reports on recent advances in HD research (in both basic and clinical sciences). Aside from participating in the plenary and other parallel sessions, attendees will also have the opportunity to meet experts in the field of HD studies in more informal settings.

In addition, the program also includes evening activities, ranging from informal meetings with industry experts to podium talks, movie night and a “Networking evening”.

MDS 2022 - International Congress of Parkinson’s Disease and Movement Disorders

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

Current and Emerging Biomarkers to Advance Clinical Research in Parkinson’s Disease

Parkinson’s disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.

From α-synuclein to advanced magnetic resonance imaging (MRI) techniques, this webinar will cover both traditional Parkinson’s disease biomarkers and the potential utility of emerging biomarkers, such as microRNA (miRNA), microbiome and multimodal approaches.

Citing longitudinal research studies and recent clinical trials, the featured speakers will share the potential utility of fluid-based biomarkers and imaging biomarkers, discussing how each may help track drug efficacy and advance clinical trials.

Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials.

-Robert Martone, Associate Director, Labcorp Drug Development
-Hiba Kazmi, PhD, Biomarker Scientist, IXICO
-Antoniya Todorova, MD, PhD, Medical Director, Labcorp